Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
Takayuki Kuroda, Haruaki Nobori, Keita Fukao, Kaoru Baba, Kazumi Matsumoto, Shinpei Yoshida, Yukari Tanaka, Ryosuke Watari, Ryoko Oka, Yasuyuki Kasai, Kae Inoue, Sho Kawashima, Alice Shimba, Yoko Hayasaki-Kajiwara, Miki Tanimura, Qianhui Zhang, Yuki Tachibana, Teruhisa Kato, Takao Shishido
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkad027
Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become established in the human population, making the need to develop safe and effective treatments critical. We have developed the small-molecule antiviral ensitrelvir, which targets the 3C-like (3CL) protease of SARS-CoV-2. This study evaluated the in vitro and in vivo efficacy of ensitrelvir compared with that of another SARS-CoV-2 3CL PI, nirmatrelvir. Methods: Cultured cells, BALB/cAJcl mice and Syrian hamsters were infected with various SARS-CoV-2 strains, including the ancestral strain WK-521, mouse-adapted SARS-CoV-2 (MA-P10) strain, Delta strain and Omicron strain. Ensitrelvir efficacy was compared with that of nirmatrelvir. Effective concentrations were determined in vitro based on virus-induced cytopathic effects, viral titres and RNA levels. Lung viral titres, nasal turbinate titres, body-weight changes, and animal survival were also monitored. Results: Ensitrelvir and nirmatrelvir showed comparable antiviral activity in multiple cell lines. Both ensitrelvir and nirmatrelvir reduced virus levels in the lungs of mice and the nasal turbinates and lungs of hamsters. However, ensitrelvir demonstrated comparable or better in vivo efficacy than that of nirmatrelvir when present at similar or slightly lower unbound-drug plasma concentrations. Conclusions: Direct in vitro and in vivo efficacy comparisons of 3CL PIs revealed that ensitrelvir demonstrated comparable in vitro efficacy to that of nirmatrelvir in cell culture and exhibited equal to or greater in vivo efficacy in terms of unbound-drug plasma concentration in both animal models evaluated. The results suggest that ensitrelvir may become an important resource for treating individuals infected with SARS-CoV-2.
Supplementary data Supplementary Methods and Figure S1 are available as Supplementary data at JAC Online.
References
Abdelnabi, Foo, Jochmans, The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern, Nat Commun,
doi:10.1038/s41467-022-28354-0Boras, Jones, Bj, Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19, Nat Commun,
doi:10.1038/s41467-021-26239-2Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for highrisk, nonhospitalized adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Imai, Iwatsuki-Horimoto, Hatta, Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development, Proc Nat Acad Sci U S A,
doi:10.1073/pnas.2009799117Imran, Arora, Asdaq, Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19, Molecules,
doi:10.3390/molecules26195795Matsuyama, Nao, Shirato, Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2002589117Mukae, Yotsuyanagi, Ohmagari, A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part, Antimicrob Agents Chemother,
doi:10.1128/aac.00697-22Mukae, Yotsuyanagi, Ohmagari, Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study, Clin Infect Dis,
doi:10.1093/cid/ciac933Owen, Allerton, Anderson, An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19, Science,
doi:10.1126/science.abl4784Sasaki, Tabata, Kishimoto, Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19, bioRxiv,
doi:10.1101/2022.02.14.480338Smith, Di, Kerns, The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery, Nat Rev Drug Discov,
doi:10.1038/nrd3287Uemura, Nobori, Sato, 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses, BioRxiv,
doi:10.1101/2022.12.14.520006Unoh, Uehara, Nakahara, Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19, J Med Chem,
doi:10.1021/acs.jmedchem.2c00117Vangeel, Chiu, Jonghe, Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res,
doi:10.1016/j.antiviral.2022.105252
